GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » Float Percentage Of Total Shares Outstanding

Ionis Pharmaceuticals (STU:ISI) Float Percentage Of Total Shares Outstanding : 84.49% (As of May. 28, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ionis Pharmaceuticals's float shares is 123.33 Mil. Ionis Pharmaceuticals's total shares outstanding is 145.97 Mil. Ionis Pharmaceuticals's float percentage of total shares outstanding is 84.49%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ionis Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ionis Pharmaceuticals's Institutional Ownership is 77.71%.

Ionis Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ionis Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=123.33/145.97
=84.49%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals (STU:ISI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (STU:ISI) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
HALO BBIO CYTK APLS MDGL EXEL CRSP KRYS RVMD IBRX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IONS:USA IONS:Mexico ISI:Germany
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Website
https://www.ionispharma.com
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (STU:ISI) Headlines

No Headlines